The 6th World Cancer Congress - 2023 has taken an initiative to join the assorted research and business groups working in this field under one rooftop to explore each and every part of cancer diseases. The World Cancer Congress - 2023 welcomes Oncologists, Radiologists, Chemotherapists, Physicians, Academicians, Academic scientists, Industry professionals, Diagnostic laboratory professionals, Post-Graduate students, Post-doctoral fellows and Trainees to be a part of this conference
ancer is the second leading cause of death worldwide. It’s crucial to remember that cancer is not one disease – it’s more than 200 cancer diseases involved. All different, unique diseases, which require different approaches for treatment. Treatments that work for some cancers don’t work for others and sometimes those treatments simply stop working. Only worldwide research will enhance our understanding of cancer and help us find and develop better, more effective treatments. And only a global search for answers will help us get to grips with this disease. . The conference will provide with an exceptional opportunity for the delegates from Universities and Institutes to interact with the world class Scientists and Industry Professionals working in the field of cancer research. The conference will provide with an exceptional opportunity for the delegates from Universities and Institutes to interact with the world class Scientists and Industry Professionals working in the field of cancer/oncology.
The 6th World Cancer Congress - 2023 will also explore the new ideas and concepts on global scale and the topics Cancer Biology & Genetics, Organ-Defined Cancers, Oncology: Sub-Specialities, Radiation Oncology, Surgical Oncology, Cancer & Stem Cell Therapy, Precision Cancer Medicine & Oncology, Cancer Biomarkers, Cancer Epidemiology, Cancer Prevention & Research, Cancer Therapy & Treatments, Cancer Pharmacology, Cancer Vaccines, Cancer Immunology & Immunotherapy, Oncology Nursing and Care, Complementary & Alternative Methods and Cancer, Cancer Awareness and Survival, Cancer: Lifestyle and Nutrition, Cancer: Psychological & Social Aspects
Meet leading oncologists, cancer researchers, pharmaceutical leaders, scientists, clinicians, physicians, doctors, health care professionals, molecular diagnosticians, clinicians, researchers, Executives/Managers and Business Delegates, Director of Laboratories, Universities, Industries, Investigators, Post-Doctoral Fellows, Research & Diagnostic Laboratories, Clinical Fellows, Students, Biomedical Research organizations, societies and associations.
The recent advancements in the cancer treatments & cancer care is accelerating. A cluster of innovative treatments, often combined with other new or existing medicines, and frequently associated with biomarkers, are emerging from the research and development pipeline. Over the past five years, 70 new oncology treatments have been launched and are being used to treat over 20 different tumour type
Southern, Eastern, and South-Eastern Asia is a diverse, densely populated region with 4.2 billion inhabitants, making up 55% of the world population. In 2018, 8.2 million new cancer cases and 5.2 million cancer deaths were estimated in the region, corresponding to around half of the cancer burden worldwide. China alone accounts for 52% of new cancer cases (4.3 million) and 55% of cancer deaths (2.9 million) in the region. Overall, cancers of the lung (1,166,200 new cases, 15% of all cases), colorectum (914,200, 11%) and female breast (845,400, 10%) are the most common cancers. (Figure 1) Lung cancer remains the leading cause of death (1,013,100 deaths, 21% of all deaths), followed by stomach (560,500, 11%) and liver cancer (554,000, 11%).
Cancer rates in the region vary widely, with nearly a fourfold difference across countries. (Map 1) Incidence rates are higher in South-Eastern Asia, and highest in the overall region in the Republic of Korea (314 cases per 100,000 population). In contrast, lower rates are seen in many countries in South Asia, including Bhutan, Sri Lanka, and India (fewer than 90 cases per 100,000). Mortality rates followed a similar pattern by subregion: Mongolia (170 per 100,000) and China (130) had the highest mortality rates, whereas Sri Lanka (51) and India (61) had the lowest rates.
The global cancer biomarker market size was valued at USD 10.3 billion in the year 2016 and is estimated to reach a value of USD 33.7 billion by 2025, growing with CAGR of 14.3 %. Growing prevalence of malignancies coupled with increasing focus on development of targeted therapies is a major factor affirming growth of this market.
Global cancer drugs market accounted for $78,238.9 million in 2015. The cancer drugs market is driven by the growing prevalence of various types of cancer, increasing demand of biological and targeted drug therapies, continuous patent expiry of key cancer drugs and the rising impact of biosimilars. Global Oncology/Cancer Drugs Market is expected to garner $111.9 billion by 2022, registering a CAGR of 7.1% during the forecast period 2014 to 2022. Recent progress in biological therapies has widened the scale of therapeutic targets for treatment of cancer with the identification of tumour cell specific genes.
This report studies the global cancer diagnostics market for the forecast period of 2015 to 2020. This market is expected to reach $13.1 Billion by 2022 from $7.1 Billion in 2015, and is poised to grow at a CAGR of 12.9% during the forecast period.